Nasdaq:US$15.72 (+0.06) | HKEX:HK$24.75 (+0.75) | AIM:£2.47 (+0.03)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 22 Nov 2007

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

1 items
a071122